EquivaBone is a proprietary combination of demineralized bone matrix (DBM) and nanocrystalline calcium phosphate that sets hard in vivo, while CarriGen is a synthetic bone substitute that utilizes the same proprietary nanocrystalline calcium phosphate technology that is found in EquivaBone. Alphatec Spine expects to distribute CarriGen in the US and Europe in the first half of 2010.
Additionally, pursuant to the supply and distribution agreement, Alphatec Spine has been granted a right of first negotiation with respect to certain technologies in the ETEX development pipeline for a non-exclusive distribution by Alphatec Spine.
Deal Type Partnership Sub-Category Marketing,Sales,Licensing Agreement,Distribution,Supply Deal Status Announced: 2009-11-05
Deal Participants
Partner 1 (Company) ETEX Corporation Partner 2 (Company) Alphatec Holdings, Inc. Partner 3 (Company) Alphatec Spine, Inc.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index